ArticleJournal of neuro-oncology2002
Growth control of C6 glioma in vivo by nerve growth factor.
Article in Journal of neuro-oncology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 35 citations in OpenAlex.
- Long-term outcomes after a randomized phase II trial of nerve growth factor eye drops for optic pathway gliomas: four-year follow-up findings in children.Journal of neuro-oncology · 2026Trial
- Nerve Growth Factor, Antimicrobial Peptides and Chemotherapy: Glioblastoma Combination Therapy to Improve Their Efficacy.Biomedicines · 2023Article
- LMO1 Plays an Oncogenic Role in Human Glioma Associated With NF-kB Pathway.Frontiers in oncology · 2022Article
- Old Stars and New Players in the Brain Tumor Microenvironment.Frontiers in cellular neuroscience · 2021Review
- hTERT Transduction Extends the Lifespan of Primary Pediatric Low-Grade Glioma Cells While Preserving the Biological Response to NGF.Pathology oncology research : POR · 2021Article
- Nerve growth factor: role in growth, differentiation and controlling cancer cell development.Journal of experimental & clinical cancer research : CR · 2016Review
- Deregulated proliferation and differentiation in brain tumors.Cell and tissue research · 2015Review
- An Eighteen Serum Cytokine Signature for Discriminating Glioma from Normal Healthy Individuals.PloS one · 2015Article
- Therapeutic effect of suicide gene-transferred mesenchymal stem cells in a rat model of glioma.Cancer gene therapy · 2012Article
- The role of stem cells in tumor targeting and growth suppression of gliomas.Biologics : targets & therapy · 2011Article
- Nerve growth factor attenuates proliferation of astrocytes via the p75 neurotrophin receptor.Glia · 2009Article
- Regulatory effect of nerve growth factor in alpha9beta1 integrin-dependent progression of glioblastoma.Neuro-oncology · 2008Article
- Cytotoxicity of human umbilical cord blood-derived mesenchymal stem cells against human malignant glioma cells.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2008Article
- Expression of cannabinoid receptors and neurotrophins in human gliomas.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2007Article
- Cytotoxicity of rat marrow stromal cells against malignant glioma cells.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2005Article
- Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model.Gene therapy · 2004Article
- Neurotrophic factor expression in childhood low-grade astrocytomas and ependymomas.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment with nerve growth factor (NGF) causes differentiation of rat C6 glioma cells and strongly inhibits their proliferation in vitro. This suggests that induction of NGF-mediated differentiation may provide a novel therapeutic approach to growth control of glial tumors. We examined the effects of NGF treatment on the growth potential of C6 glioma, which expressed NGF receptor in vivo. C6 glioma cells (1 x 10(6) cells/10 microl) were transplanted into the rat striatum. After 4 days, the animals were given successive injections of 100 ng NGF into the growing tumor at every 4 days (n = 10 rats). Controls were subjected to identical procedures with vehicle which did not contain NGF (n = 10 rats). At 14 days after transplantation, we evaluated the tumor volume, proliferative cell index (PCI) based on the MIB-1 immunoreactivity and enzyme activities related to energy metabolism by enzyme histochemistry. We found that the NGF treatment markedly reduced the tumor volume of the C6 glioma (34.00 +/- 8.47 mm3 to 7.22 +/- 4.92 mm3, p < 0.01). NGF treatment also decreased the PCI (33.34 +/- 9.57% to 3.85 +/- 3.56%, p < 0.01) with a negative correlation with tumor volume (r = 0.972, p < 0.01), and the hexokinase (HK) and glucose-6-phosphate dehydrogenase (G6PDH) activities (p < 0.01 and p < 0.01, respectively) which reflect the demand for nucleic acid synthesis for proliferation through the glycolytic and pentose phosphate pathways. The present results demonstrate for the first time that inhibition of tumor cell proliferation of C6 glioma by NGF occurs in vivo, probably through the NGF-mediated differentiation of C6 glioma cells which has been observed in in vitro studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.